LIXT.NASDAQLixte Biotechnology Holdings, INC

S-1: Lixte Biotechnology Seeks to Register Shares for Resale Following Recent Financing

Sentiment:

S-1 Registration Statement

📋All filings for Lixte Biotechnology Holdings, INC
🔒Login to Follow

Lixte Biotechnology Holdings files an S-1 registration statement to allow selling stockholders to resell shares of common stock issuable upon exercise of warrants obtained in a recent financing.

Delay expectedA clinical trial hold due to serious adverse events could delay or halt the development of the company's product candidate.
Capital raiseThe company is registering for resale 467,393 shares of common stock issuable upon exercise of warrants.The company could receive up to $1,094,095 from the cash exercise of these warrants.The company is evaluating various alternatives to obtain the capital required to fund its operations and maintain its listing on Nasdaq, including merger or acquisition opportunities (including reverse mergers) and funding transactions involving a change in control.
Worse than expectedThe company has a history of losses and expects to continue incurring losses in the near term.There is substantial doubt about the company's ability to continue as a going concern.The company is currently not in compliance with Nasdaq continued listing requirements.

Summary

  • Lixte Biotechnology Holdings, Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 467,393 shares of its common stock.
  • These shares are issuable upon the exercise of warrants (2025 Warrants and 2025 Placement Agent Warrants) that were issued in a private offering on February 11, 2025.
  • The company will not receive any proceeds from the sale of these shares by the selling stockholders, but will receive proceeds upon the cash exercise of the warrants, potentially totaling up to $1,094,095.
  • Lixte intends to use any cash proceeds from warrant exercises for working capital and continuing operating expenses, including further clinical development of its lead compound LB-100.
  • The company's common stock is listed on The Nasdaq Capital Market under the symbol LIXT, with a last reported sale price of $1.22 per share on April 2, 2025.
  • The company is currently facing challenges in maintaining compliance with Nasdaq's minimum stockholders' equity requirement and has requested a hearing to appeal a potential delisting.
  • Lixte is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies, primarily inhibitors of protein phosphatase 2A (PP2A).
  • Its lead drug candidate, LB-100, is currently being tested in clinical trials for various cancers, including Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma.
  • The company has collaboration agreements with several institutions, including MD Anderson Cancer Center and the Netherlands Cancer Institute, to conduct clinical trials of LB-100 in combination with other cancer therapies.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive aspects such as ongoing clinical trials and collaborations, the company's financial challenges, including losses, going concern doubts, and Nasdaq compliance issues, weigh heavily on the overall sentiment.

Positives

  • LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma.
  • LB-100 has also been shown to enhance the effectiveness of commonly used anti-cancer drugs in animal models of melanoma, breast cancer and sarcoma.
  • The company has collaboration agreements with several institutions, including MD Anderson Cancer Center and the Netherlands Cancer Institute, to conduct clinical trials of LB-100 in combination with other cancer therapies.
  • The company has licensed exclusively NIHs intellectual property rights claimed for a Cooperative Research and Development Agreement (CRADA) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs.

Negatives

  • The company has a history of losses and expects to continue incurring losses in the near term.
  • There is substantial doubt about the company's ability to continue as a going concern.
  • The company is currently not in compliance with Nasdaq continued listing requirements.
  • A clinical trial hold due to serious adverse events could delay or halt the development of the company's product candidate.
  • The principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs observed in the clinical trial that was launched in August 2024.
  • The Institutional Review Board (the IRB) of the Netherlands Cancer Institute (NKI) has put the colorectal cancer study on hold.

Risks

  • The company's business faces significant risks related to the development and regulatory approval of its product candidates.
  • A clinical trial hold due to serious adverse events could delay or halt the development of LB-100.
  • The company may not be able to regain compliance with Nasdaq listing standards, which could result in delisting.
  • The company will have to seek to raise additional funds to fund its operations, including the various clinical trials being currently conducted or will be conducted in the future.
  • The price of the company's common stock or warrants might fluctuate substantially.
  • Provisions of the Warrants issued in the 2023 Financing and 2025 Financing could discourage an acquisition of the company by a third party.
  • An active, liquid and orderly trading market for the company's common stock may not develop, the price of its stock may be volatile, and investors could lose all or part of their investment.

Future Outlook

The company's longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical companies with major programs in cancer. The company expects its operating losses will continue, or even increase, at least through the near term.

Industry Context

Lixte Biotechnology operates in the competitive biopharmaceutical industry, focusing on cancer therapies. The company's approach involves identifying new targets for drug development and commercializing cancer therapies, particularly PP2A inhibitors. The document highlights the potential of LB-100 to enhance the effects of chemotherapy and immunotherapy, addressing the unmet medical need to improve cancer treatment outcomes. The company's collaborations with leading cancer centers and pharmaceutical companies indicate its efforts to advance its clinical programs and expand its market reach.

Comparison to Industry Standards

  • The document mentions collaborations with GSK and Roche, which are major players in the pharmaceutical industry, indicating that Lixte is aligning itself with industry standards by partnering with established companies.
  • The clinical trials being conducted by Lixte are investigator-initiated, which is a common practice in the biopharmaceutical industry to explore new treatment options and combinations.
  • The document references the use of doxorubicin as the global standard for initial treatment of advanced soft tissue sarcomas, indicating that Lixte is comparing its LB-100 combination therapy to the current standard of care.
  • The company's focus on enhancing immunotherapy responses aligns with the growing trend of immunotherapy in cancer treatment.
  • The company's approach of operating with a minimum of overhead and raising funds to support each stage of development is a common strategy for smaller biopharmaceutical companies.

Stakeholder Impact

  • Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges and potential delisting.
  • Employees' job security may be affected by the company's financial situation and potential strategic alternatives.
  • Patients may benefit from the development of LB-100 as a potential cancer therapy.
  • The company's suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

  • Continue clinical trials for LB-100 in various cancer types.
  • Seek strategic partnerships or licensing agreements with pharmaceutical companies.
  • Regain compliance with Nasdaq listing requirements.
  • Respond to the IRB's questions regarding the SAEs observed in the clinical trial of LB-100 combined with atezolizumab.

Key Dates

DateDescription
March 22, 2006Research on the LB-100 series was initiated under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurologic Disorders and Stroke or NINDS of the National Institutes of Health or NIH
July 31, 2019Effective date of the Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group (Grupo Espaol de Investigacin en Sarcomas or GEIS), Madrid, Spain.
March 9, 2021Clinical trial of LB-100 combined with an FDA-approved standard regiment for treatment of untreated extensive-stage disease small cell lung cancer was initiated.
October 8, 2021Entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (NKI), one of the worlds leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, for a term of three years.
October 13, 2022Announced that the Spanish Agency for Medicines and Health Products (Agencia Espaola de Medicamentos y Productos Sanitarios or AEMPS) had authorized a Phase 1b/randomized Phase 2 study of LB-100, our lead clinical compound, plus doxorubicin, versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS).
June 2, 2023Effected a one-for-ten reverse split of outstanding shares of common stock.
June 30, 2023The Phase 1 portion of the study began in the quarter ended June 30, 2023 to determine the recommended Phase 2 dose of the combination of doxorubicin and LB-100.
July 20, 2023Sold 583,334 shares of common stock at a price of $6.00 per share to an institutional investor and raised gross proceeds of approximately $3,500,000.
September 20, 2023Announced an investigator-initiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (PD-1) blocking antibody of GSK plc (GSK), dostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).
October 3, 2023Entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the operating budget being funded by us.
January 29, 2024Announced the entry of the first patient into this clinical trial.
February 23, 2024Entered into a Patent License Agreement (the License Agreement) with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH).
February 11, 2025Entered into a Securities Purchase Agreement (the Purchase Agreement) with two institutional investors (the Selling Stockholders).
February 13, 2025Sold 434,784 shares of common stock at a price of $2.415 per share and raised gross proceeds of approximately $1,050,000.
February 25, 2025Announced that we had added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Companys proprietary compound LB-100 with GSKs dostarlimab to treat ovarian clear cell cancer.
March 11, 2025Entered into Amendment No. 1 to the Collaboration Agreement effective March 11, 2025 that relieved us of the financial obligation to support the randomized Phase 2 portion of the clinical trial contemplated in the Collaboration Agreement of approximately $3,095,000.
December 31, 2026Clinical trial commenced during the quarter ended June 30, 2023 and to be completed and a report prepared by December 31, 2026.
December 31, 2027We currently expect that this clinical trial will be completed by December 31, 2027.
February 13, 2030Such Warrants had an initial exercise price of $2.29 per share, were immediately exercisable upon issuance, and expire five years thereafter on February 13, 2030.

Keywords

Lixte Biotechnology, LB-100, clinical trials, cancer therapy, warrants, registration statement, PP2A inhibitors, financing, Nasdaq, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.